We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAi
News

Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAi

Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAi
News

Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAi

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAi"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dr. Shankar has already successfully used RNAi to dramatically suppress HIV infection in mice by knocking down three key genes which prevented the HIV infection from spreading.

Bioo Scientific’s T3 Technology will allow Dr Shankar to precisely target the delivery of siRNAs in vivo into T-cells, although it can be used to target any cell type. The patent pending T3 Technology functions by conjugating an RNAi agent carrier to a monoclonal antibody to produce a conjugate, which is then loaded with an RNAi agent such as siRNA or miRNA molecules. The RNAi agent loaded conjugate is administered to an animal where it binds to and is internalized by cells recognized by the monoclonal antibody. The RNAi agent is then released to reduce the expression of its intended target. T3 technology can propel the validation of animal experimentation, leading to a better understanding of cellular pathways, the identification of novel drug targets, and the ability to more efficiently deliver RNAi agents as drugs.

 “I am delighted to join forces with Bioo Scientific in the development of an advanced monoclonal antibody based technology for targeted delivery of siRNA to T cells and potentially other cell types” Dr. Shankar said.  “By combining our scientific expertise and resources, we can speed up the development of robust enabling platforms for efficient delivery to desired cells and tissues in vivo which is critical for translating siRNAs into a novel class of drugs to treat human diseases.”

Advertisement